Tau positron emission tomography (PET) imaging has potential for elucidating changes in the deposition of neuropathological tau aggregates that are occurring during the progression of Alzheimer's disease (AD). This work investigates in vivo kinetics, quantification strategies and imaging characteristics of a novel tau PET radioligand 18 F-MK-6240 in humans. Methods Fifty-one individuals ranging from cognitively normal young controls to persons with dementia underwent T1-weighted magnetic resonance imaging (MRI), and 11 C-PiB and 18 F-MK-6240 PET imaging. PET data were coregistered to the MRI and time-activity curves were extracted from regions of interest to assess 18 F-MK-6240 kinetics. The pons and inferior cerebellum were investigated as potential reference regions. Reference tissue methods (Logan graphical analysis (LGA) and multilinear reference tissue method (MRTM2)) were investigated for quantification of 18 F-MK-6240 distribution volume ratios (DVRs) in a subset of nineteen participants. Stability of DVR methods was evaluated using truncated scan durations. Standard uptake value ratio (SUVR) estimates were compared to DVR estimates to determine the optimal timing window for SUVR analysis.
INTRODUCTION

AD Pathophysiology
Neurofibrillary tau tangles (NFTs) and beta-amyloid (Aβ) plaques are neuropathological hallmarks of AD that accumulate decades prior to neurodegeneration and symptomatic onset of disease (1) (2) (3) .
Neuropathological staging of NFTs and Aβ plaques suggests these protein aggregates follow hierarchical spatiotemporal patterns during the AD progression that are indicative of disease severity. Specific to tau, neuropathological staining in predetermined slices indicates NFTs are first observed in the transentorhinal cortex (Braak stage I), followed by the hippocampus (stage II), and then spread laterally to the inferior temporal cortex (stage III) and subsequently spread throughout the neocortex in an ordered pattern (stages IV-VI) (4) . In vivo biomarker studies evaluating Aβ and tau are mostly consistent with postmortem findings and suggest a temporal biomarker cascade that putatively begins with detectable Aβ accumulation, followed by tau aggregation and ultimately neurodegeneration and deficits in cognition (5) (6) (7) . Recently, cross-sectional analyses of Aβ and tau PET imaging have indicated these biomarkers follow hierarchical patterns that may be useful for in vivo disease staging (7, 8) . Characterization of the temporal sequencing of the biomarker cascade shows promise for predicting future cognitive decline, particularly at the patient level, which could dramatically improve late-life planning and outcomes of clinical prevention trials (9) .
Tau PET Imaging
Starting in 2013 PET ligands for detecting NFTs have undergone rapid development (for review see (10) ). Initial tau PET imaging studies have indicated approximate concordance between in vivo imaging (11) (12) (13) and hierarchical patterns observed in neuropathological staging of NFT's. These studies also demonstrate relationships between tracer specific binding and various measures of cognition, neurodegeneration and delineation of clinical groups. These early results suggest tau PET imaging will play a critical role in disentangling the complex interactions between Aβ, neurofibrillary tau, neurodegeneration and their impact on cognition and late-stage disease outcomes (14) . While these studies highlight the promise for tau imaging, they primarily focus on comparing clinically impaired individuals to cognitively healthy controls and do not address the potential of these ligands for identifying tau in early-stage disease where disease intervention is likely to be more effective. Additionally, some tau PET ligands have suffered from lack of specificity for tau (THK series) (15, 16) , nonpolar radiometabolites (PBB3) (17) , and off-target binding that interferes with regions of interest for monitoring early-stage tau deposition such as the hippocampus (AV-1451 and THK series) (12) . Recently, 18 F-MK-6240 has shown high in vitro affinity for NFTs and no in vivo off-target binding in the basal ganglia in non-human primates (18) . These preclinical results indicate 18 F-MK-6240 has potential for selective imaging of AD tau aggregates in humans, and may be more sensitive for detecting tau in regions associated with early NFT deposition (i.e. early Braak regions). The central aims of this work are to 1) evaluate the in vivo pharmacokinetics, 2) investigate dynamic and static reference tissue methods for quantification of specific binding, 3) characterize the in vivo spatial distribution of binding related to tau, and 4) identify regions of potential off-target binding of 18 F-MK-6240 in humans ranging from cognitively unimpaired young adults to clinically diagnosed probable AD.
MATERIALS AND METHODS
Participants and Recruitment
Participants (n=51) were recruited from the University of Wisconsin-Madison Alzheimer's Disease Research Center and its affiliated clinics, or the Wisconsin Registry for Alzheimer's Prevention (19) , a longitudinal study following late-middle-aged individuals enriched for AD risk. AD dementia individuals were determined based on clinical diagnosis of probable AD (diagnosis was not informed by AD biomarkers). All other participants were grouped as young controls (27-45 years) , older controls, cognitive decliners, and mild cognitive impairment (MCI). The latter three diagnoses were based on longitudinal neuropsychological evaluation and consensus diagnosis (19) . Descriptive statistics for the groups are summarized in Table 1 .
Written informed consent was obtained from all individuals prior to participation. This study was conducted under the University of Wisconsin-Madison Institutional Review Board and the Federal Drug Administration Investigational New Drug mechanism for 18 F-MK-6240 and 11 C-PiB PET studies. No adverse events were reported for administration of 18 F-MK-6240.
MRI and Anatomical Delineation
All participants underwent a T1-weighted 3D inversion recovery fast spoiled gradient-echo sequence on a 3T MRI scanner (Signa 750, GE Healthcare) with a 32-channel head coil (inversion time, 450 ms; repetition time, 8.1 ms; echo time, 3.2 ms; flip angle, 12°; matrix, 256×256×156; voxel dimensions, 1×1×1 mm; field of view, 256 mm; slice thickness, 1.0 mm). The T1-w image was corrected for magnetic field inhomogeneity (SPM12) and tissue class segmented for white matter (WM), gray matter (GM), and cerebrospinal fluid (CSF). The deformation field obtained from the tissue-class segmentation was used to inverse warp regions of interest (ROIs) from MNI template space to native MRI space.
Radiochemical Synthesis 11 C-PiB Radiochemical synthesis of 11 C-PiB was performed as previously described (20) yielding specific activity of 650±161 MBq/nmol (mean±SD, n=48). 18 F-MK-6240 18 F-MK-6240 was synthesized similar to previously reported methods (18) with modifications to improve 18 F-MK-6240 radiochemical yield and automated using a Sofie ELIXYS (21) and a computer controlled fraction collection, solid-phase extraction and formulation module previously validated for human use (22) . 18 F-Fluoride was isolated from bulk target 18 μm C6-phenyl 110 Å 250x10 mm, 45/55 ethanol/10 mM sodium acetate, 3-4 mL/min). The 18 F-MK-6240 fraction was collected in a bottle containing 35 mL sterile water for injection, USP and underwent solid phase extraction (tC18 Sep-Pak Plus Short, rinsed with 15 mL sterile water for injection, USP, eluted with 1 mL dehydrated ethanol). The eluate was diluted in 9 mL bacteriostatic 0.9% sodium chloride for injection, USP and was 0.22 μm filtered and collected in a vented 10 mL sterile empty vial. A summary of radiochemistry results for 18 F-MK-6240 syntheses can be found in Table 2. PET Imaging PET scans were acquired using a Siemens ECAT EXACT HR+ tomograph. 11 C-PiB Dynamic 11 C-PiB scans were acquired from 0-70 minutes after a nominal 555 MBq injection for all participants except young controls, who were assumed to be devoid of Aβ pathology based on their age (3) . DVRs (LGA, cerebellar GM reference region) were estimated (20) and a global DVR threshold (23) was used to ascertain PiB status (PiB(+) or PiB(-)) for descriptive purposes. 18 F-MK-6240 A total of 51 participants underwent 18 F-MK-6240 PET scans following a nominal 370 MBq injection. A subset of nineteen participants (3 young controls, 6 older controls, 2 cognitive decliners, 1 MCI, 7 probable AD) were scanned dynamically from bolus tracer injection for a total duration of either 90, 105, or 120 minutes. The remaining 32 participants were scanned for 60 minutes following a 60-minute uptake period. 18 F-MK-6240 PET images were reconstructed using optimized subset expectation maximization (ECAT v7.2.2, 4 iterations, 16 subsets, brain mode on, ramp filter, voxel size 2.57x2.57x2.425 mm, matrix size 128x128x63, corrections applied: segmented attenuation, detector deadtime, scatter, detector normalization and radioisotope decay).
Data Extraction, Quantification and Analysis of Simplified Methods
The reconstructed 18 F-MK-6240 PET time series was interframe realigned and coregistered to T1w MRI (SPM12). HYPR-LR denoising (24) was applied in native PET space to the realigned PET scans with full dynamic data used for DVR analysis (see below). Parametric 18 F-MK-6240 standard uptake value ratio (SUVR=C(t)/Cref(t)) images were generated using data from 70-90 minutes post injection (Cref, inferior cerebellar GM reference region). 18 F-MK-6240 time-activity curves (TACs) were extracted from the coregistered PET time series in native T1 space. Pons and off-target ROIs were delineated in MNI space based on an in-depth imaging review of 18 F-MK-6240 parametric SUVR images in individual cases and SUVR images averaged across control subjects (see below). Additionally, an inferior cerebellum ROI was generated for reference region analysis by combining Automated Anatomical Labeling (AAL, Neurodegenerative Diseases Institute, Université de Bordeaux) ROIs (93,94,101-104) in native T1 space and eroding the mask to limit spill-in from adjacent WM, CSF. The inferior cerebellum (henceforth referred to as "cerebellum") was used, as opposed to the entire cerebellar GM, due to focal binding observed in the the superior cerebellum and the adjacent tentorium cerebelli, and to avoid contamination from occipital cortex spillover observed in AD participants with high occipital retention. Brain penetrance and evaluation of reference regions (cerebellum and pons) was performed by comparing the standard uptake value (SUV = CPET / ID x mass) across all subjects. DVRs were determined at the ROI level using reference tissue LGA (25) and MRTM2 (26) for all participants with full dynamic acquisitions (n=19).
LGA and MRTM2 were chosen as they are amenable to generation of parametric images for voxel-wise analyses.
LGA and MRTM2 fitting times (t*) were determined by comparing DVR estimates using stepwise t* values (Bland-Altman plots). Stability of the DVR as a function of scan duration was evaluated within each method by regressing DVR estimates derived from truncated data (i.e. shorter scans) onto DVRs derived from full-length scans.
SUVRs derived from stepwise 20-minute windows starting 40 minutes post-injection were regressed onto
LGA and MRTM2 DVR to assess the quantitative accuracy of SUVR.
ROIs consisted of the AAL atlas, which was restricted to voxels with GM probabilities greater than thirty percent, and manually segmented ROIs drawn in MNI space in regions with apparent off-target binding. Regions for regression analyses included all AAL ROIs (n=90) except cerebellar regions and also did not include the manually segmented off-target ROIs. This was done to capture the full range of binding observed in this study throughout the entire brain. 
RESULTS
Reference Region Evaluation
SUV TACs indicated consistent washout across all 51 subjects in the cerebellum and the pons (Fig.   1 ), and brain penetrance similar to other PET radioligands (peak SUV~2.5-5). The cerebellum was used as reference region for the remainder of the analyses due to the larger ROI volume (17.1±3.8 cm 3 vs. 2.2±0.4 cm 3 ) and previous validation with other tau PET radioligands (27, 28) .
Pharmacokinetic Evaluation of 18 F-MK-6240
Target-to-cerebellum TACs (Fig. 2) plateaued around 70 minutes post injection for moderate binding subjects and regions, but were still increasing at 90 minutes in neocortical regions of the highest binding AD subjects (SUVR>3). TACs relative to cerebellum in off-target regions that included bone marrow (ethmoid sinus, clivus, sphenotemporal buttress) were increasing throughout the entire 120-minute scan duration ( Fig. 2) and had SUVR values similar to the parahippocampus and the inferior temporal gyrus of PiB(+) AD and MCI individuals around 90 minutes. Similarly, TACs in the meninges relative to cerebellum were increasing throughout the entire 120-minute scan and varied considerably in magnitude across subjects (SUVR 0.5-3.5 at 120 minutes). High meninges binding was more frequent in individuals that did not exhibit specific binding in NFT associated regions.
Quantification of 18 F-MK-6240 Specific Binding
The initial fitting times (t*) for LGA (k2=0.04 min -1 , based on median MRTM2 estimates) and MRTM2 were 35 and 30 minutes, respectively. Regression (table 3) (Table 3) with SUVR underestimating DVR (LGA and MRTM2) for 20-minute windows starting earlier than 60 minutes. Plots of SUVR onto DVR appeared bi-linear, with values around 1 having a different slope than values above ~1.5 DVR. Fitting parameters closest to unity between SUVR and MRTM2 were chosen as the criteria for the timing window (70-90 min) used for parametric SUVR image generation. 18 
F-MK-6240 Imaging Features
Regions of potential off-target binding identified using mean SUVR images of controls and individual cases included the ethmoid sinus, clivus, sphenotemporal buttress, pineal gland, substantia nigra, superior anterior vermis, superior cerebellum, and the meninges and varied in magnitude and spatial extent across all subjects (Fig. 5 ). In some extreme cases (6 of 51), meninges binding was observed to spill into adjacent cortical areas. In two cases, focal binding was observed in benign calvarial lesions. Elevated binding was generally not observed in the basal ganglia, choroid plexus (except 1 moderate case), or other regions of the brain that appeared to preclude binding quantification in NFT associated regions. All individuals that were PiB(+) and indicated visually elevated binding in pathological tau-associated regions followed patterns consistent with neuropathological NFT staging (Fig. 6 ).
DISCUSSION
PET radiopharmaceuticals for detecting NFTs in AD require 1) a high selectivity over other amyloids When evaluating quantification methods for tau PET imaging within the context of clinical research, it is desirable to reduce the PET scan duration to accommodate aging and symptomatic individuals that can experience discomfort, and to maximize the efficiency of the tomograph usage in multi-tracer studies.
While DVR estimates were stable using as little as 60 minutes of dynamic data, SUVR quantification with static imaging may be more practical for persons with AD since the overall emission scan duration can be reduced to 20-minutes and still achieve binding estimates comparable to DVR methods.
The selection of the scan duration for SUVR estimation with 18 F-MK-6240 involves a trade-off between unwanted off-target spill-in from sites outside of the brain with the accuracy of quantification. In particular, regions that could potentially influence cortical binding estimates (ethmoid, clivus and meninges) had SUVRs that were increasing through 120 minutes. Notably, signal in the ethmoid sinus was observed to spill into the orbitofrontal cortex, which could limit quantification of tau-related signal. In contrast, SUVRs in target regions were in agreement with DVR estimates when using data from 70-90 minutes, although SUVRs in target regions were still increasing in higher binding AD subjects during this window. Taken together, this suggests that the 70-90 minute acquisition window will produce accurate binding estimates while reducing potential contamination from off-target binding. This may need to be re-evaluated in studies looking to characterize changes (longitudinal and therapeutic intervention) in SUVR in high binding AD subjects.
A limitation of this study was the absence of arterial blood sampling, which would have provided the gold standard comparison for the DVR and SUVR estimates and could elucidate the source of the discrepancy between LGA and MRTM2 methods. However, since there has been extensive evaluation of the cerebellum as a reference region with other tau tracers (27) (28) (29) (30) ,the cerebellum is used in large-scale tau PET neuroimaging studies (12, 13, 31) , and previous preclinical work did not observe non-polar radiometabolites (18) , we believe the results presented in this work will accurately represent comparisons with arterial derived specific binding estimates, but this must be confirmed. Additionally, the mechanism of tracer accumulation in non-NFT target regions is unknown and should be further investigated. Lastly, this study sample was selected to encompass a wide range of disease states, but further investigation of associations between MK-6240 and other disease biomarkers and cognition in a larger cohort is needed.
CONCLUSION
In a sample of individuals ranging from young cognitively unimpaired controls to individuals with AD dementia, 18 F-MK-6240 had favorable kinetics for DVR and SUVR quantification by 90-minutes postinjection, low off-target binding in the brain, and binding patterns consistent with neuropathological staging of neurofibrillary tau. These characteristics indicate 18 F-MK-6240 PET imaging will play a critical role in advancing the understanding of the role of tau pathology in Alzheimer's disease. 
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